Ignite Creation Date:
2024-05-06 @ 8:10 AM
Last Modification Date:
2024-10-26 @ 11:57 AM
Study NCT ID:
NCT02689921
Status:
UNKNOWN
Last Update Posted:
2018-09-28
First Post:
2016-02-04
Brief Title:
NEOADjuvant Aromatase Inhibitor and PertuzumabTrastuzumab for Women With Breast Cancer
Sponsor:
Midwestern Regional Medical Center
Organization:
Midwestern Regional Medical Center
Study Overview
Official Title:
A Phase II Study of NEOADjuvant Aromatase Inhibitor and PertuzumabTrastuzumab NEOADAPT
Status:
UNKNOWN
Status Verified Date:
2018-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NEOADAPT
Brief Summary:
This is a prospective single-arm phase II study of 32 evaluable patients treated with NEOADjuvant Aromatase inhibitor and PertuzumabTrastuzumab NEOADAPT without chemotherapy for hormone receptor positive HR ie Estrogen Receptor positive ER andor Progesterone Receptor positive PR HER2 localized non-metastatic stage I - IIb breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ML30001 | OTHER | Genentech Inc | None |